US EditionPublished • loading... • Updated
Novo Nordisk to Buy U.S.-Based Akero for Up to $5.2 Billion for Promising Liver Drug
Novo Nordisk will pay $54 per share upfront plus $6 per share contingent on approval for efruxifermin, targeting treatment of MASH with high unmet medical need.
- On Thursday, Novo Nordisk said it would buy Akero Therapeutics for up to $5.2 billion to add experimental liver drug efruxifermin in CEO Mike Doustdar's first major acquisition.
- Strategic fit drives the acquisition, given MASH's link to diabetes and obesity, as over 40% have type 2 diabetes and more than 80% live with obesity.
- Under the terms, Novo will pay $54 per share in cash, totaling 4.7 billion USD, with Akero shareholders receiving a $6 per share CVR if approved by June 30, 2031.
- Market response reflected investor views on strategic growth and risks as Akero shares jumped more than 19% while Novo Nordisk shares fell nearly 2%, with a $4 billion hit to the 2025 free cash flow outlook.
- Efruxifermin's clinical data position it as a potentially differentiated therapy; it is in phase 3 SYNCHRONY programme targeting F2-F3 and F4 patients and may be a `cornerstone therapy`, Mike Doustdar said.
Insights by Ground AI
12 Articles
12 Articles
Novo Nordisk to Buy Akero Therapeutics for up to $5.2 Billion
·New York, United States
Read Full Article
Novo Nordisk to buy Akero for up to $5.2 billion for promising liver drug
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources12
Leaning Left2Leaning Right2Center4Last UpdatedBias Distribution50% Center
Bias Distribution
- 50% of the sources are Center
50% Center
L 25%
C 50%
R 25%
Factuality
To view factuality data please Upgrade to Premium
